DexCom Inc (DXCM)

Currency in USD
66.37
-0.69(-1.03%)
Closed·
66.38+0.01(+0.02%)
·
DXCM is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
66.0067.15
52 wk Range
54.1193.25
Key Statistics
Prev. Close
67.06
Open
67.1
Day's Range
66-67.15
52 wk Range
54.11-93.25
Volume
2.07M
Average Vol. (3m)
5.74M
1-Year Change
-14.66%
Book Value / Share
6.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DXCM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
85.27
Upside
+28.48%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth

DexCom Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

DexCom Inc Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Inc SWOT Analysis


Analyst Outlook
Price targets range from $80 to $102, averaging $91.25, reflecting mixed sentiment as DexCom balances market leadership against competitive threats from Abbott and potential regulatory hurdles.
Financial Headwinds
Despite robust sales of $1.04 billion in Q1 2025, DexCom faces margin challenges from quality initiatives and supply issues, prompting revised forecasts for 2026.
Growth Catalysts
Expansion into the Type 2 diabetes market and the upcoming G7 15-day sensor launch present significant opportunities, with 6 million new covered lives expected by year-end 2025.
Diabetes Tech Leade
DexCom dominates the continuous glucose monitoring market with strong sales growth and record new patient starts, despite facing recent margin pressures from supply chain challenges.
Read full SWOT analysis

DexCom Inc Earnings Call Summary for Q3/2025

  • DexCom exceeded Q3 2025 expectations with EPS of $0.61 (7.02% above forecast) and revenue of $1.21 billion (2.54% above forecast), while maintaining stable stock price post-earnings.
  • Revenue grew 22% year-over-year with strong performance in both U.S. ($852M, +21%) and international markets ($357.4M, +22%), resulting in record-high quarterly earnings.
  • The company raised its 2025 revenue guidance to $4.63-$4.65 billion, projecting 15% growth and anticipating record new patient starts in 2026, particularly in the Type 2 diabetes market.
  • DexCom launched new products including Dexcom Smart Basal and a 15-day sensor system, while maintaining a strong financial position with over $3.3 billion in cash and cash equivalents.
  • Jake Leach, President and Interim CEO, emphasized the company's customer-centric approach, while CFO Jereme Sylvain highlighted ongoing operational improvements to deliver margin growth.
Last Updated: 10/30/2025, 06:07 PM
Read Full Transcript
DexCom investor slides for Q3/2025
DexCom Q3 2025 slides
Last Update: Oct 30, 2025
See full investor slides

Compare DXCM to Peers and Sector

Metrics to compare
DXCM
Peers
Sector
Relationship
P/E Ratio
35.9x18.1x−0.6x
PEG Ratio
4.63−0.180.00
Price / Book
9.5x4.3x2.6x
Price / LTM Sales
5.7x2.6x3.2x
Upside (Analyst Target)
26.6%35.8%42.7%
Fair Value Upside
Unlock−1.8%6.8%Unlock

Analyst Ratings

25 Buy
4 Hold
0 Sell
Ratings:
29 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 85.27
(+28.48% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Mizuho
Buy78.00+17.52%75.00MaintainDec 17, 2025
Leerink Partners
Buy92.00+38.62%81.00MaintainDec 16, 2025
Citi
Buy77.00+16.02%75.00MaintainDec 11, 2025
Morgan Stanley
Buy75.00+13.00%63.00UpgradeDec 02, 2025
Evercore ISI
Hold68.00+2.46%-New CoverageNov 25, 2025

Earnings

Latest Release
Oct 30, 2025
EPS / Forecast
0.61 / 0.57
Revenue / Forecast
1.21B / 1.18B
EPS Revisions
Last 90 days

DXCM Income Statement

People Also Watch

67.17
FISV
-0.55%
820.29
MCK
-0.85%
296.01
ADSK
-1.18%
330.11
UNH
-0.62%
194.91
ORCL
-1.17%

FAQ

What Is the DexCom (DXCM) Stock Price Today?

The DexCom stock price today is 66.37

What Stock Exchange Does DexCom Trade On?

DexCom is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for DexCom?

The stock symbol for DexCom is "DXCM."

What Is the DexCom Market Cap?

As of today, DexCom market cap is 25.89B.

What Is DexCom's Earnings Per Share (TTM)?

The DexCom EPS (TTM) is 1.80.

When Is the Next DexCom Earnings Date?

DexCom will release its next earnings report on Feb 05, 2026.

From a Technical Analysis Perspective, Is DXCM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has DexCom Stock Split?

DexCom has split 1 times.

How Many Employees Does DexCom Have?

DexCom has 10250 employees.

What is the current trading status of DexCom (DXCM)?

As of Jan 01, 2026, DexCom (DXCM) is trading at a price of 66.37, with a previous close of 67.06. The stock has fluctuated within a day range of 66.00 to 67.15, while its 52-week range spans from 54.11 to 93.25.

What Is DexCom (DXCM) Price Target According to Analysts?

The average 12-month price target for DexCom is USD85.26923, with a high estimate of USD112 and a low estimate of USD68. 25 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +28.48% Upside potential.

What Is the DXCM After Hours Price?

DXCM's last after hours stock price is 66.38, the stock has decreased by 0.01, or 0.02%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.